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background: Increased time in therapeutic range (TTR) on warfarin is often used as a balance between preventing stroke without excess bleeding. 
This study evaluated stroke or systemic embolism (SE) and bleeding risks of antithrombotic therapies in non-valvular atrial fibrillation (NVAF) 
patients within an integrated healthcare system.
methods: Patients age ≥18 years and newly diagnosed with NVAF (index date) were identified between 01/01/2006-12/31/2011 within Kaiser 
Permanente Southern California’s databases, categorized by baseline CHADS2 risks, and followed until 12/31/2012. The rate of stroke/SE and 
major bleeding events were evaluated for: 1) warfarin TTR ≥55%, 2) warfarin TTR <55%, 3) aspirin (ASA) only, and 4) no antithrombotic therapy. The 
55% threshold was selected as the lower bound of reported means from previous studies.
results: Among 23,297 patients with CHADS2 ≥1, 1,782 stroke/SE events occurred during 59,979 person-years of follow-up. The warfarin 
TTR ≥55% category had the lowest stroke/SE rate (Rate =0.87 [95% CI: 0.71-1.04] per 100 person-years, 3.24 [2.76-3.71] for TTR<55%, 2.73 
[2.52-2.94] for ASA only, 4.71 [4.39-5.03] for no antithrombotic therapy), and was associated with a 73% lower risk of stroke/SE compared to 
TTR <55% and 81% lower stroke/SE risk compared to no therapy. Stroke/SE was increased in higher CHADS2 risk categories (1.64 for CHADS2=1, 
3.18 for CHADS2=2, 4.88 for CHADS2≥3), and the impact of TTR ≥55% was greater in higher CHADS2 groups (TTR ≥55% vs. TTR <55%: RR=0.40 
for CHADS2=1, 0.28 for CHADS2=2, 0.19 for CHADS2≥3). Major bleeding in TTR ≥55% was 60% lower compared to TTR <55%, but 18% higher 
compared to ASA only therapy (4.90 [4.53-5.28] for TTR ≥55%, 12.32 [11.41-13.23] for TTR <55%, 4.15 [3.88-4.42] for ASA only therapy, 8.00 
[7.57-8.44] for no therapy). The higher bleeding rate found for no therapy may be based on contraindications to anticoagulation that precluded 
warfarin use.
conclusions: Warfarin TTR ≥55% had a lower risk of stroke/SE and major bleed compared to TTR <55%, and a lower risk of stroke/SE compared 
to ASA only. Future studies should address high bleeding and stroke risk with warfarin TTR <55% and modifiable factors to improve outcomes.
